Nasdaq · Healthcare
HARROW, INC. (HROW)
As-reported financials and recent SEC filings for HARROW, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$272.3M
Net income
$-5.1M
Net margin
-1.9%
Diluted EPS
$-0.14
ROE
-9.9%
P/E (TTM)
—
Market cap
$1.57B
Debt / equity
4.8×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $272.3M | $199.6M | $130.2M | $88.6M | $72.5M |
| Gross profit | $204.4M | $150.4M | $90.6M | $63.2M | $54.3M |
| Operating income | $30.5M | $8.8M | $431,000 | $1.9M | $1.6M |
| Net income | $-5.1M | $-17.5M | $-24.4M | $-14.1M | $-18.0M |
| Diluted EPS | $-0.14 | $-0.49 | $-0.75 | $-0.51 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →8-K2026-06-22
View on EDGAR →8-K2026-06-03
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-18
View on EDGAR →Go deeper on HROW
Search HARROW, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.